Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | APEX1 | P27695 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005224 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| SCHEMBL1040145 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| SCHEMBL548835 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| SCHEMBL6895464 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| Cetrimonium SCHEMBL237554 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| SCHEMBL25414052 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| SCHEMBL126381 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| SCHEMBL238047 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| SCHEMBL6681513 | 1.00 | DNM1 (0.60) | DNM1APAF1HSP90AA1RAD52RECQL | |
| Hydrochloric Acid SCHEMBL18192375 | 0.98 | DNM1 (0.61) | DNM1APAF1HSP90AA1RAD52RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717481-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-08-08 | — | — | US | claimed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | claimed |
| US-11253478-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-02-22 | — | — | US | claimed |
| EP-3755148-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNanoPharma (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200390737-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2020-12-17 | — | — | US | claimed |
| WO-2020065541-A1 | MICROEMULSIONS AND METHODS OF USE | MOROCCANOIL ISRAEL, LTD. (IL) | 2020-04-02 | — | — | WO | claimed |
| WO-2019165240-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2019-08-29 | — | — | WO | claimed |
| US-20180250229-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-09-06 | — | — | US | claimed |
| US-9974747-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-05-22 | — | — | US | claimed |
| US-9974746-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-05-22 | — | — | US | claimed |
| WO-2003080024-A2 | NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080023-A2 | FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | ELAN PHARMA INTERNATIONAL LTD. | 2003-10-02 | — | — | US | claimed |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | ELAN PHARMA INTERNATIONAL LTD. | 2003-09-25 | — | — | US | claimed |
| WO-2003066021-A2 | DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-08-14 | — | — | WO | claimed |
| US-20030137067-A1 | Compositions having a combination of immediate release and controlled release characteristics | ELAN PHARMA INTERNATIONAL LTD. | 2003-07-24 | — | — | US | claimed |
| US-20030095928-A1 | Nanoparticulate insulin | ELAN PHARMA INTERNATIONAL LIMITED | 2003-05-22 | — | — | US | claimed |
| WO-2003030872-A2 | COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2003-04-17 | — | — | WO | claimed |
| WO-2003024425-A1 | NANOPARTICULATE INSULIN FORMULATIONS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390737-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | TUBAL3, TUBB6, TUBA1A | ACHE 308/4885DNM1 2064/4885APAF1 3792/4885 |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | PACSIN2, MAP3K20, MAP3K2 | ACHE 234/4885DNM1 2500/4885APAF1 1665/4885 |
| US-20030137067-A1 | Compositions having a combination of immediate release and controlled release characteristics | NAPA, CD63, RPL36 | ACHE 211/4885DNM1 2386/4885APAF1 1274/4885 |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | LPO, LCT, CTSA | ACHE 11/4885DNM1 3252/4885APAF1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.